Langtian Pharmaceutical Technology (Wuhan) Co., Ltd.

(1) Evaluate the tolerability and pharmacokinetic characteristics of the inhalation preparation after a single dose in healthy subjects; (2) Compare the pharmacokinetic behavior of the inhalation preparation and the injection preparation in healthy subjects using pharmacokinetic parameters as the primary endpoint evaluation indicators, and calculate the absolute bioavailability of the inhalation preparation; (3) Compare the exposure of the inhalation preparation and the injection preparation in the nasopharynx and alveoli of healthy subjects; Evaluate the tolerability and pharmacokinetic characteristics of the inhalation preparation after multiple doses in healthy subjects.